![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/remegen-showcases-research-results-at-american-society-of-clinical-oncology-asco-2024-annual-meeting-highlighting-its-prolific-innovation-in-global-cancer-treatment-302164875.html
https://www.prnewswire.com/news-releases/remegen-reports-proof-of-concept-phase-iii-clinical-study-results-for-self-developed-potential-first-in-class-antibody-drug-conjugate-rc88-302162619.html
https://www.prnewswire.com/news-releases/remegen-completes-patient-enrollment-in-two-phase-iii-clinical-trials-using-telitacicept-for-treatment-of-iga-nephropathy-and-primary-sjogrens-syndrome-302151195.html
https://www.prnewswire.com/news-releases/remegen-celebrates-world-lupus-day-2024-with-increased-lupus-visibility-through-vital-knowledge-sharing-302142173.html
https://www.prnewswire.com/news-releases/remegens-telitacicept-rc18-granted-fast-track-designation-by-united-states-fda-for-treatment-of-primary-sjogrens-syndrome-302106576.html
https://www.prnewswire.com/news-releases/remegen-presents-oral-presentation-on-evaluation-of-its-proprietary-disitamab-vedotin-rc48-for-cervical-cancer-at-esgo-2024-302084877.html
https://www.prnewswire.com/news-releases/world-cancer-day-2024-remegen-announces-three-significant-developments-in-the-global-fight-against-cancer-narrowing-the-care-gap-302051872.html
https://www.prnewswire.com/news-releases/remegens-rc88-obtained-fda-fast-track-designation-heralds-new-hope-for-ovarian-cancer-patients-302033529.html
https://www.prnewswire.com/news-releases/remegen-announces-continued-inclusion-of-telitacicept-and-disitamab-vedotin-in-china-national-reimbursement-drug-list-ensuring-continuous-accessibility-of-innovative-drugs-for-more-patients-302017793.html
https://www.prnewswire.com/news-releases/remegen-announces-publication-of-results-from-two-phase-ii-studies-for-disitamab-vedotin-in-latest-issue-of-journal-of-clinical-oncology-jco-301998515.html